SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
Katrine Meyer Lauritsen(Steno Diabetes Centers), Esben Søndergaard(Aarhus University Hospital), Lars Poulsen Tolbod(Aarhus University Hospital), Lars Christian Gormsen(Aarhus University), Troels Krarup Hansen(Steno Diabetes Centers), Niels Møller(Aarhus University Hospital), Mogens Johannsen(Aarhus University), Jakob Hansen(Aarhus University), Henrik Wiggers(Aarhus University Hospital)
Cited by 65
Related Papers
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|714
Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
|European Journal of Heart Failure|2016|561
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
|Circulation|2019|513
Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study
|Journal of the American Heart Association|2017|235
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
|American Journal of Physiology-Heart and Circulatory Physiology|2010|165